Evolus (EOLS) Total Current Liabilities (2017 - 2026)
Evolus' (EOLS) quarterly Total Current Liabilities came in at $68.0 million in Q1 2026, up 20.97% YoY from $56.2 million in Q1 2025, and down 9.67% on a QoQ basis from $75.3 million in Q4 2025.
Evolus (EOLS) Total Current Liabilities (2017 - 2026) Analysis & Trends
Evolus (EOLS) has 10 years of Total Current Liabilities data on file, last reported at $68.0 million in Q1 2026.
- Quarterly Total Current Liabilities rose 20.97% year-over-year to $68.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $68.0 million (up 20.97% YoY) and the FY2025 annual result came in at $75.3 million, up 19.61% from the prior year.
- Total Current Liabilities eased to $68.0 million in Q1 2026, from $75.3 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $75.3 million in Q4 2025 to a low of $40.7 million in Q1 2023.
- A 5-year average of $54.3 million and a median of $51.5 million in 2022 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2022 — Total Current Liabilities sank 53.56% — and 2024, when it surged 30.88%.
- Tracing EOLS's Total Current Liabilities over 5 years: stood at $46.5 million in 2022, then increased by 3.83% to $48.3 million in 2023, then surged by 30.38% to $63.0 million in 2024, then gained by 19.61% to $75.3 million in 2025, then fell by 9.67% to $68.0 million in 2026.
- The last three Total Current Liabilities figures came in at $68.0 million (Q1 2026), $75.3 million (Q4 2025), and $66.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.29 Bn | 43.33 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 43.57 Bn | 39.92 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 32.09 Bn | 30.41 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.32 Bn | 19.66 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.79 Bn | 17.91 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.99 Bn | 11.46 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.08 Bn | 9.91 Bn | - | 1.79 Bn |
| 10 | Evolus | 542.93 Mn | 497.76 Mn | 57.18 Mn | 98.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 98.73 Mn |
| Mar 31, 2026 | 68.02 Mn |
| Dec 31, 2025 | 75.31 Mn |
| Sep 30, 2025 | 66.71 Mn |
| Jun 30, 2025 | 63.75 Mn |
| Mar 31, 2025 | 56.23 Mn |
| Dec 31, 2024 | 62.96 Mn |
| Sep 30, 2024 | 60.82 Mn |
| Jun 30, 2024 | 54.12 Mn |
| Mar 31, 2024 | 46.80 Mn |
| Dec 31, 2023 | 48.29 Mn |
| Sep 30, 2023 | 48.54 Mn |
| Jun 30, 2023 | 41.35 Mn |
| Mar 31, 2023 | 40.68 Mn |
| Dec 31, 2022 | 46.51 Mn |
| Sep 30, 2022 | 51.27 Mn |
| Jun 30, 2022 | 51.53 Mn |
| Mar 31, 2022 | 40.70 Mn |
| Dec 31, 2021 | 57.66 Mn |
| Sep 30, 2021 | 71.30 Mn |